Immune Design Corporation
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Immune Design Corporation
The winners of the XPRIZE will move on to collaborate with OpenCovidScreen, a non-profit founded by scientists and business leaders, to drive needed innovation through “Open Science.”
The former Medivation CEO, after a brief detour heading up Axovant, is returning to oncology, but the new company is keeping details about the seven cancer drug programs in its pipeline under wraps.
The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.
Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.